April 2020 in “Online journal of complementary & alternative medicine” Some medications can help increase sexual desire and function in women.
A new acne cream effectively reduced acne in trials and awaits FDA approval.
The FDA did not approve a testosterone drug because of safety concerns.
September 2015 in “Korean Journal of Clinical Pharmacy” Dutasteride is highly effective for hair loss treatment in Korea, with more side effects than finasteride.
1 citations,
September 2022 in “Nepal journal of dermatology, venereology & leprology” Apremilast shows promise for several skin conditions but needs more research.
November 2023 in “Brain Sciences” Some medications might contribute to male infertility, with finasteride showing a high number of reports.
May 2021 in “Letters in Applied NanoBioScience” Pranlukast and mirabegron may work as new diabetes drugs.
11 citations,
July 2020 in “Scientific Reports” Statins may be linked to reproductive organ conditions, and their risks should be monitored.
October 2024 in “Andrology” Paternal drug exposure can harm fertility, pregnancy outcomes, and offspring health, with specific drugs linked to various reproductive issues.
May 2016 in “The Journal of Sexual Medicine” 6 citations,
January 2021 in “Journal of the American Academy of Dermatology” PRP treatments for hair loss need standard protocols to be reliable.
3 citations,
July 2022 in “BMC chemistry” The methods accurately measure finasteride and tadalafil in Entadfi™ capsules for quality control.
Finasteride and testosterone are the drugs most linked to male infertility, but many other potential drugs may be under-reported.
Some drugs may increase the risk of obstructive sleep apnea, while others like certain biologics might decrease it.
May 2016 in “The Journal of Sexual Medicine” Younger people (median age 35) experience more PFS-like symptoms with 1mg finasteride; more research needed.
3 citations,
September 2020 in “Molecular Brain” The anti-viral drug Elvitegravir may protect brain cells from damage related to neurodegenerative diseases.
October 2023 in “Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy” New, eco-friendly methods accurately measure TDF and FNS in a new urologic medication.
January 2023 in “RSC Advances” The study developed accurate, precise, and environmentally friendly methods to measure Finasteride and Tadalafil in a new FDA-approved combination.
1 citations,
April 2018 in “Sleep” Finasteride increases risk of sleep apnea and insomnia.
October 2021 in “European urology open science” August 2018 in “Journal of The American Academy of Dermatology” 110 citations,
August 2016 in “Drugs” Minoxidil is the only FDA-approved topical drug for treating male or female pattern hair loss, and other medications like finasteride and dutasteride can also increase hair growth.
30 citations,
January 2000 in “Dermatologic Clinics” Finasteride and minoxidil are effective FDA-approved treatments for androgenetic alopecia.
15 citations,
October 2017 in “Journal of Cosmetic and Laser Therapy” FDA-cleared devices may help treat hair loss, but more research needed; consult dermatologist before use.
9 citations,
November 2021 in “PubMed” FDA-approved low-level light/laser therapy devices can significantly increase hair density in people with pattern hair loss.
September 2022 in “Hair transplant forum international” JAK inhibitors like baricitinib are a new FDA-approved treatment for alopecia areata, but safety data is incomplete.
January 2018 in “Springer eBooks” Lasers are FDA-approved for permanent hair reduction, not removal, and more research is needed to improve treatments.
January 2012 in “Human health handbooks” Low-level light therapy is FDA-approved for male pattern hair loss, increases hair count and strength, and is considered safe for use.
May 2011 in “Value in Health” No current patient-reported outcome measure fully meets FDA requirements for alopecia treatments.
1 citations,
October 2022 in “Molecular therapy” The FDA approved the first gene therapy for a blood disorder after overcoming early challenges and demonstrating patient benefits.